Four decades of Danaher operating companies, organized by subsidiary — every material Danaher, Fortive, Envista, and Veralto operating company across the three spinoffs and the three current life-sciences segments.
This is the subsidiaries ledger companion to the Institute's Danaher acquisitions record. Where that page catalogs Danaher's acquisition transactions chronologically — ~87 material deals from 1984 through today — this page catalogs the operating companies Danaher has owned across four decades, organized alphabetically by subsidiary and tracking each company's current disposition. Every material Danaher operating company appears on this page: Cepheid (2016, molecular diagnostics), Cytiva (2020, ~$21.4B from GE Life Sciences — Danaher's largest deal ever), Aldevron (2021, ~$9.6B for plasmid DNA and mRNA services), Abcam (2023, ~$5.7B for antibody reagents), Pall Corporation (2015, ~$13.8B for filtration), Beckman Coulter Life Sciences and Diagnostics (2011, ~$6.8B), Leica Microsystems and Leica Biosystems (2005 legacy), Radiometer (2003, blood-gas analyzers), SCIEX and Molecular Devices (2010, mass spectrometry), Phenomenex (2016, chromatography), IDBS (2017, laboratory informatics), plus the entire cohorts that moved to Fortive (July 2016 — Fluke, Tektronix, Matco, Gilbarco Veeder-Root, Kollmorgen), Envista (September 2019 — Nobel Biocare, Ormco, KaVo Kerr, DEXIS), and Veralto (September 2023 — Hach, Videojet, ChemTreat, Trojan, X-Rite, Pantone, Esko). This ledger is a living reference: as Danaher closes new bolt-ons or announces further separations, the row is added, the status updates, and the sitemap timestamp bumps. Nothing here is investment advice. Everything here is a fact-checkable practitioner reference for a very specific question — what does forty years of operating-company assembly under the Danaher Business System actually look like in ledger form?
This is the subsidiaries ledger, distinct from the acquisitions record. The Danaher acquisitions record catalogs Danaher's individual transaction history — ~87 material deal announcements and closes from 1984 through today, ordered chronologically. This ledger catalogs the operating companies inside Danaher (and its Fortive, Envista, and Veralto spinoff cohorts) organized by subsidiary. The two records are complementary: read together they show both the deal history and the operating book. This ledger is the reference format practitioners use when they need to ask, 'Does Danaher still own Cepheid,' 'What did Danaher pay for Beckman Coulter,' or 'Where did Fluke and Tektronix go after 2016.'
Organized by subsidiary, not by year. Unlike the acquisitions record, which is chronological, this ledger is sorted alphabetically by operating-company name. Each row tracks the segment at time of ownership (Biotechnology, Life Sciences, Diagnostics, Environmental & Applied Solutions, or Divested), the year Danaher acquired the business, the approximate deal consideration in USD (undisclosed for several older transactions), the country of origin, the current status (Current Danaher / Spun to Fortive / Spun to Envista / Spun to Veralto / Sold / Merged), and a one-line practitioner note on the operating company's role and disposition.
Reflects current and historic ownership, plus the three spinoffs. The Danaher operating-company book has been reshaped by three major spinoffs: Fortive Corporation (July 2016) took the industrial-technology and instrumentation portfolio — Fluke, Tektronix, Matco Tools, Gilbarco Veeder-Root, Kollmorgen, and Jacobs Vehicle Systems. Envista Holdings (September 2019) took the dental portfolio — Nobel Biocare, Ormco, KaVo Kerr, DEXIS Digital Imaging. Veralto Corporation (September 2023) took the environmental-and-applied portfolio — Hach, Trojan Technologies, ChemTreat, Videojet, Linx Printing, X-Rite, Pantone, Esko. Every subsidiary carries a status flag indicating whether it is currently a Danaher operating company, a Fortive operating company, an Envista operating company, a Veralto operating company, or has been sold outright.
Framed for professional research audiences. This ledger is written for practitioners in M&A, private equity, healthcare-and-life-sciences analysis, and industrial capital-allocation study who need a fact-checkable reference for the Danaher operating-company book. Every row is a one-line answer to a specific query. This is the reference set for the study of operating-system-driven acquisition compounding — the Danaher Business System applied across four decades and three portfolio structures — that sits at the center of the modern industrial-M&A tradition.
Five structural observations across forty years of Danaher operating-company assembly — the how-Danaher-builds pattern that the ledger below documents subsidiary by subsidiary.
(a) Segment restructuring cadence — from industrials to life-sciences purity. The Danaher of 1984-2000 was a diversified industrial roll-up: hand tools (Matco), test-and-measurement (Fluke, Tektronix), motion controls (Kollmorgen), vehicle service (Chicago Pneumatic-era), and gasoline-station instrumentation (Gilbarco Veeder-Root). The Danaher of 2000-2010 pivoted into water quality (Hach, Trojan), product identification (Videojet), and dental (Nobel Biocare, Ormco, KaVo) alongside continued industrial. The Danaher of 2011-2020 pivoted decisively into life sciences and diagnostics (Beckman Coulter, Leica, Pall, Cepheid, Cytiva) while systematically shedding the older cohorts through the Fortive (2016), Envista (2019), and Veralto (2023) spinoffs. The Danaher of 2020-today is a pure-play Biotechnology, Life Sciences, and Diagnostics business. The subsidiaries ledger reads as the record of that four-decade transformation.
(b) The Danaher Business System applied to acquisitions. Every operating company inside Danaher runs on the Danaher Business System (DBS) — the kaizen-and-value-stream-mapping operating discipline codified by the Rales brothers in the early 1990s and installed into every acquired subsidiary within the first 100 days. DBS is the mechanism by which small industrial acquisitions of the 1980s and life-sciences platforms of the 2010s alike produce Danaher-caliber margins. The spinoffs (Fortive, Envista, Veralto) all took DBS-equivalent operating systems with them and continue to run them; the acquired subsidiaries that predate a Danaher-era ownership (Beckman Coulter, Pall, Cytiva, Cepheid) each underwent a multi-year DBS conversion that visibly improved operating metrics inside two years of close.
(c) The three spinoffs — why Fortive, why Envista, why Veralto. Danaher's three major spinoffs each solved a specific portfolio-focus problem. Fortive (July 2016) separated the industrial-technology and instrumentation portfolio (Fluke, Tektronix, Matco, Gilbarco Veeder-Root, Kollmorgen) so that Danaher could focus capital allocation on the emerging life-sciences and diagnostics platform following the 2015 Pall acquisition. Envista (September 2019) separated the dental portfolio (Nobel Biocare, Ormco, KaVo Kerr, DEXIS) because dental had distinct customer, capital, and cyclical characteristics from the life-sciences segments — Envista could pursue its own strategy at its own cost of capital. Veralto (September 2023) separated the environmental-and-applied portfolio (Hach, Trojan, ChemTreat, Videojet, X-Rite, Pantone, Esko) so that Danaher could operate as a pure-play life-sciences and biotech leader alongside Thermo Fisher, Merck KGaA MilliporeSigma, and Sartorius. Each spinoff was a stock-for-stock tax-free distribution to shareholders; each retained a version of DBS.
(d) Cytiva as the platform pivot. The February 2019 announcement and March 2020 close of the Cytiva acquisition — approximately $21.4B in cash for GE Life Sciences's biopharma hardware and consumables business (subsequently rebranded Cytiva) — is the single most consequential capital-allocation event in modern Danaher history. Cytiva more than doubled the size of the Biotechnology segment, added the flagship bioprocessing-hardware position (single-use bioreactors, chromatography resins, filtration media) that Danaher had been building toward since Pall (2015), and repositioned the company as the pure-play bioprocessing peer to Sartorius, Merck KGaA MilliporeSigma, and Thermo Fisher. The 2021 Aldevron acquisition (~$9.6B for plasmid DNA and mRNA services) and the 2023 Abcam acquisition (~$5.7B for antibody reagents) extended the Cytiva platform pivot into upstream biologics tools. Post-Cytiva, Danaher's ability to serve the entire pharmaceutical manufacturing workflow was structurally different from its pre-2020 position.
(e) The tuck-in acquisition machine. Alongside the signature platform-defining deals (Beckman Coulter, Pall, Cepheid, Cytiva, Aldevron, Abcam), Danaher runs a continuous tuck-in acquisition program — smaller bolt-ons that extend an existing segment platform. Phenomenex (2016) added chromatography consumables to Life Sciences. IDBS (2017) added laboratory informatics. Precision NanoSystems (2023) added lipid-nanoparticle-formulation capability to Biotechnology. Aperio (via Leica Biosystems, 2012) added digital pathology. HemoCue (via Radiometer) added point-of-care hemoglobin testing. The tuck-in cadence — roughly five to ten per year across current segments — is where much of the ongoing operating-margin improvement is captured. This ledger tracks the material tuck-ins but not the smaller undisclosed adds; the exhaustive record is the acquisitions page.
Every material Danaher operating company from the 1984 Rales-brothers founding through today, sorted alphabetically by subsidiary — the reference format practitioners use when researching a specific operating company. Anchored by the current Biotechnology anchors (Cytiva, Aldevron, Pall Corporation), the Life Sciences platform (Beckman Coulter Life Sciences, Leica Microsystems, SCIEX, Abcam, Phenomenex), the Diagnostics platform (Cepheid, Beckman Coulter Diagnostics, Leica Biosystems, Radiometer), and the three spinoff cohorts — Fortive (Fluke, Tektronix, Matco, Gilbarco Veeder-Root, Kollmorgen), Envista (Nobel Biocare, Ormco, KaVo Kerr, DEXIS), and Veralto (Hach, Trojan, ChemTreat, Videojet, X-Rite, Pantone, Esko). Sortable by subsidiary, segment, acquisition year, consideration, and status. Search by operating-company name (Cepheid, Cytiva, Beckman Coulter, Leica, Pall, Aldevron, Abcam, Radiometer, SCIEX, Phenomenex, IDBS, Hach, Videojet, ChemTreat, Trojan, X-Rite, Fluke, Tektronix, Nobel Biocare, Ormco, KaVo Kerr) or by country (United States, Germany, Sweden, United Kingdom, Denmark, Switzerland, Canada). Every row is a fact-checkable reference. This is a living dataset — updated as Danaher closes new bolt-ons or restructures the operating-company book.
| Subsidiary | Segment | Acquired | Consideration | Country of Origin | Status | Practitioner Note |
|---|
Across seven years Danaher executed three tax-free spinoff distributions that collectively transformed the company from a diversified industrial-and-life-sciences conglomerate into a pure-play biotechnology, life sciences, and diagnostics leader. Each spinoff was a stock-for-stock distribution to shareholders; each took a distinct portfolio of operating companies; each retained a version of the Danaher Business System operating discipline.
What went with it: Fluke Corporation, Tektronix, Matco Tools, Gilbarco Veeder-Root, Kollmorgen, Jacobs Vehicle Systems, plus the industrial-motion and hand-tools portfolio. Ticker: NYSE: FTV. Why: Separate the industrial-technology and instrumentation portfolio from the accelerating life-sciences platform following the 2015 Pall acquisition.
What went with it: Nobel Biocare, Ormco, KaVo Kerr, DEXIS Digital Imaging, plus the remaining dental portfolio. Ticker: NYSE: NVST. Why: Separate the dental businesses whose customer, capital, and cyclical characteristics were distinct from life-sciences segments; Envista could pursue its own strategy at its own cost of capital.
What went with it: Hach, Trojan Technologies, ChemTreat (water quality and treatment), Videojet Technologies, Linx Printing (product identification), X-Rite, Pantone, Esko (packaging color and design). Ticker: NYSE: VLTO. Why: Complete the transformation to a pure-play life-sciences, biotech, and diagnostics leader; separate the environmental-and-applied portfolio.
Practitioner reading: Every spun-off subsidiary retains its own history under a new corporate parent. If you are researching Fluke, Tektronix, or Matco Tools today, you are researching Fortive operating companies — not Danaher. If you are researching Nobel Biocare, Ormco, or KaVo Kerr today, you are researching Envista operating companies. If you are researching Hach, Videojet, ChemTreat, or Pantone today, you are researching Veralto operating companies. This ledger tracks each subsidiary's home at every point in its Danaher-family history.
Announced February 25, 2019; closed March 31, 2020 for approximately $21.4B in cash. Danaher acquired Cytiva — formerly the biopharma-hardware and consumables business inside GE Life Sciences — in the largest single acquisition in the company's history. Cytiva more than doubled the size of the Biotechnology segment and added the flagship bioprocessing hardware and consumables position: single-use bioreactors, chromatography resins, filtration media, plus the AKTA and Xcellerex product families. Post-close, the business was rebranded from 'GE Biopharma' to Cytiva.
Why it matters as a subsidiary-level event. Pre-Cytiva, Danaher was a life-sciences and diagnostics leader with a small emerging biotechnology position (mostly Pall, which had been acquired in 2015 for ~$13.8B for filtration). Post-Cytiva, Danaher was a pure-play bioprocessing peer to Sartorius, Merck KGaA MilliporeSigma, and Thermo Fisher — able to serve the entire pharmaceutical manufacturing workflow. The 2021 Aldevron acquisition (~$9.6B for plasmid DNA and mRNA services) and the 2023 Abcam acquisition (~$5.7B for antibody reagents) built out the platform Cytiva anchored.
Funding structure. ~$3B common stock issuance to GE + ~$1.7B mandatory convertible preferred + balance in cash-and-debt. The convertible preferred was subsequently converted per its terms. Cytiva now sits at the center of the Biotechnology segment alongside Aldevron, Pall Life Sciences, Precision NanoSystems, and the associated bioprocessing consumables and instrument book.
Post the September 2023 Veralto spinoff, Danaher operates in three segments. Approximate subsidiary counts reflect named operating companies in each segment; smaller undisclosed bolt-ons and sub-brand product lines are not counted separately.
Anchored by Cytiva (2020, ~$21.4B) and Aldevron (2021, ~$9.6B). Includes Pall Life Sciences, Precision NanoSystems (2023 acquisition, LNP formulation), and the associated bioprocessing consumables and instrument businesses. Roughly the largest revenue segment and the fastest-growing. Serves biopharma manufacturing across upstream, downstream, and single-use workflows.
Includes Beckman Coulter Life Sciences, Leica Microsystems (2005 legacy), SCIEX (2010 mass spectrometry), Molecular Devices, Phenomenex (2016 chromatography), IDBS (2017 lab informatics), and (from December 2023) Abcam (antibody reagents). Serves academic, government, and pharmaceutical research customers.
Anchored by Beckman Coulter Diagnostics (2011), Cepheid (2016 molecular diagnostics), and Leica Biosystems (via 2005 Leica Microsystems). Includes Radiometer (2003 blood-gas analyzers), HemoCue (via Radiometer), Mammotome, and the associated clinical-lab and pathology book. Serves hospitals, clinical laboratories, and point-of-care diagnostic customers.
The three current segments collectively contain roughly 20-25 named operating companies. Historic subsidiaries that moved to Fortive (2016), Envista (2019), or Veralto (2023) appear in this ledger for reference but are not part of the current three-segment Danaher operating book.
The most common practitioner questions about the Danaher subsidiaries ledger.
Cepheid is a Sunnyvale, California molecular diagnostics company that operates the GeneXpert automated PCR platform — the point-of-care nucleic-acid testing system that runs cartridges for tuberculosis, HIV viral load, sexually transmitted infections, hospital-acquired MRSA, influenza, and (from March 2020) SARS-CoV-2. Danaher acquired Cepheid in November 2016 for approximately $4B and integrated it into the Diagnostics segment. Cepheid remains a wholly-owned Danaher operating company today, sitting alongside Beckman Coulter Diagnostics, Leica Biosystems, Radiometer, HemoCue, and Mammotome in the Diagnostics segment. Cepheid GeneXpert was the flagship COVID-era rapid-molecular-testing platform globally — the growth surge in 2020-2022 made Cepheid one of Danaher's most consequential single acquisitions of the 2010s.
Danaher's largest single acquisition is the March 2020 close of the Cytiva transaction — the biopharma-hardware and consumables business Danaher acquired from General Electric Life Sciences for approximately $21.4B. Announced February 2019 and closed March 31, 2020, Cytiva more than doubled the size of the Danaher Biotechnology segment and repositioned the company decisively toward pharmaceutical-process manufacturing. The next-largest deals in Danaher history are the August 2015 Pall Corporation acquisition (~$13.8B for filtration and separation), the August 2021 Aldevron acquisition (~$9.6B for plasmid DNA and mRNA services), the June 2011 Beckman Coulter acquisition (~$6.8B for clinical diagnostics and life sciences instruments), the December 2023 Abcam acquisition (~$5.7B for antibody reagents), and the November 2016 Cepheid acquisition (~$4B for molecular diagnostics).
The Danaher Business System is the operating discipline installed into every Danaher operating company across four decades — a lean-manufacturing and continuous-improvement framework adapted by Steven and Mitchell Rales in the 1980s from Toyota Production System principles and codified in the early 1990s. DBS runs on kaizen events (weekly improvement workshops), value-stream mapping, daily management visualization, standardized policy deployment, and a specific set of DBS tools (Problem Solving Process, Kaizen Basics, Transactional Process Improvement, Growth Room). DBS is why Danaher's compounding record is best understood as an operating compounder rather than a portfolio compounder: every acquired subsidiary is folded into the DBS operating rhythm within the first 100 days, and DBS is the mechanism by which the Rales brothers converted the industrial roll-up of the 1990s into the life-sciences and biotech leader of the 2020s. Fortive (spun 2016), Envista (spun 2019), and Veralto (spun 2023) all continued to run DBS-equivalent operating systems after separation.
Danaher completed the spinoff of Veralto Corporation (NYSE: VLTO) on September 30, 2023 — the third major spinoff after Fortive (2016) and Envista (2019). Veralto took with it the entire Environmental & Applied Solutions segment: Hach and Trojan Technologies (water quality and UV disinfection), ChemTreat (industrial water treatment), Videojet Technologies and Linx Printing (product identification and marking), and X-Rite / Pantone / Esko (packaging color and design). The strategic rationale was portfolio focus — the spinoff completed Danaher's four-decade transformation from a diversified industrial conglomerate into a pure-play Life Sciences, Biotechnology, and Diagnostics business. Post-Veralto, Danaher operates three segments (Biotechnology, Life Sciences, Diagnostics) and no longer participates in water, product-marking, packaging, or industrial-instrumentation markets. Veralto shareholders received one share of Veralto for every three shares of Danaher held.
No. Fluke Corporation, the Everett, Washington maker of handheld electronic test and measurement instruments, was acquired by Danaher in 1998 for approximately $625M and became one of the anchor businesses of Danaher's industrial-technology segment for nearly two decades. In July 2016 Danaher spun off Fluke as part of the Fortive Corporation (NYSE: FTV) separation, which took with it Fluke, Tektronix, Matco Tools, Gilbarco Veeder-Root, Kollmorgen, Jacobs Vehicle Systems, and the entire industrial-and-motion portfolio Danaher had assembled from the 1980s through the mid-2010s. Fluke is currently a Fortive operating company; it is no longer inside Danaher. This spinoff pattern is one of the reasons the Danaher subsidiaries ledger must be organized by both current and historic ownership — a subsidiary can be Danaher today, Fortive tomorrow, and possibly further separated after that.
Post the September 2023 Veralto spinoff, Danaher operates in three segments. Biotechnology is anchored by Cytiva (acquired 2020 for ~$21.4B from GE Life Sciences) and Aldevron (acquired 2021 for ~$9.6B for plasmid DNA / mRNA services) and includes Precision NanoSystems and the associated bioprocessing consumables and instrument businesses — roughly 40% of Danaher revenue and the fastest-growing segment. Life Sciences includes Beckman Coulter Life Sciences, Leica Microsystems, SCIEX, Molecular Devices, Phenomenex, IDBS, and (from December 2023) Abcam — the instruments-and-reagents portfolio serving academic, government, and pharmaceutical-research customers. Diagnostics is anchored by Beckman Coulter Diagnostics, Cepheid, Leica Biosystems, Radiometer, HemoCue, and Mammotome — clinical-lab, molecular, pathology, and blood-gas testing. Danaher's transformation from the diversified conglomerate of the 2000s to this three-segment life-sciences leader is the signature capital-allocation story of the modern industrial-M&A record.
Danaher announced the acquisition of Cytiva (then still branded 'GE Biopharma' inside GE Life Sciences) on February 25, 2019 and closed the transaction on March 31, 2020 for approximately $21.4B in cash. It is by a substantial margin the largest single acquisition in Danaher history — roughly one-and-a-half times the 2015 Pall Corporation deal (~$13.8B) and more than double the 2021 Aldevron deal (~$9.6B). The acquisition was funded through approximately $3B of common stock issuance to GE, approximately $1.7B of mandatory convertible preferred stock, and the balance in cash-and-debt. Post-close, Danaher rebranded the business as Cytiva (from 'GE Biopharma') and integrated it as the anchor of a newly-formed Biotechnology segment. The deal repositioned Danaher from a diagnostics-and-life-sciences instruments company into a bioprocessing-hardware leader adjacent to Sartorius, Merck KGaA MilliporeSigma, and Thermo Fisher — the platform pivot that defined the Danaher of the 2020s.
Danaher operates approximately 20-25 named operating companies across its three segments (Biotechnology, Life Sciences, Diagnostics) today. Across four decades of Danaher history there have been approximately 50-60 material operating-company subsidiaries when the three spun-off cohorts are counted — roughly a dozen in the current three-segment Danaher, approximately 15 that moved to Fortive in the 2016 industrial-technology spinoff, another six or seven that moved to Envista in the 2019 dental spinoff, and roughly a dozen that moved to Veralto in the 2023 water-and-marking spinoff. This ledger tracks each material subsidiary alphabetically with its current status (Current Danaher / Fortive / Envista / Veralto / Sold / Merged). Danaher's tuck-in acquisitions of small bolt-on businesses continue at pace (approximately five to ten per year), so the operating-company count moves with each fiscal-year disclosure.
The Danaher subsidiaries ledger is the operating-company companion to the Institute's Danaher acquisitions record. Read alongside the following pages.
Educational reference. Not investment advice. Not a solicitation. Not affiliated with Danaher Corporation, Fortive Corporation, Envista Holdings Corporation, Veralto Corporation, or any of their subsidiaries or affiliates, nor with Steven M. Rales, Mitchell P. Rales, Rainer M. Blair, James A. Lico, Amir Aghdaei, Jennifer L. Honeycutt, or any past or present Danaher-family executive. The Baratelli Institute publishes under the Lowe v. SEC publisher exception; neutral positioning maintained throughout. Deal figures cited in this ledger are sourced primarily to Danaher Corporation annual reports (SEC 10-K filings), Fortive, Envista, and Veralto Form 10 filings and subsequent 10-Ks, portfolio-company filings and prospectuses, contemporaneous press coverage (Reuters, Bloomberg, Financial Times, The Wall Street Journal, Barron's, Endpoints News, Fierce Biotech, GEN), and standard practitioner references. Dollar amounts are approximate; where original consideration was denominated in EUR, GBP, DKK, CHF, or other non-USD currencies the USD equivalent is directional and reflects contemporaneous FX rates. Several older tuck-in transactions are individually undisclosed and are flagged with "Undisclosed" or "n/d" rather than fabricating precision. Corrections welcome via the link in the footer.
“The Danaher Business System is our foundation, our culture, and our engine of change. It drives every aspect of our culture and performance, and it is why we win.”